Brian K. Link

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy, Chip Stewart, Andrew Dunford et al. · Nature Medicine · 2018 · 2K citations · Full text

Medicine, Hematology, Oncology +12

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq et al. · Blood · 2017 · 1.7K citations · Full text

Medicine, Hematology, Oncology +10

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Jens G. Lohr, Petar Stojanov, Michael S. Lawrence et al. · Proceedings of the National Academy of Sciences · 2012 · 980 citations · Full text

Life Sciences, Genetics, Oncology +17

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Carla Casulo, Michelle Byrtek, Keith Dawson et al. · Journal of Clinical Oncology · 2015 · 844 citations · Full text

Medicine, Immunology, Oncology +11